Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1998-07-08
1999-11-16
Azpuru, Carlos
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424430, 424431, 424432, 424433, 424435, 424436, 424443, 424494, A61F 1302, A61F 606, A61F 614, A61K 916
Patent
active
059853131
ABSTRACT:
A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.
REFERENCES:
patent: 4330338 (1982-05-01), Banker
patent: 4385078 (1983-05-01), Onda et al.
patent: 4462839 (1984-07-01), McGinley et al.
patent: 4518433 (1985-05-01), McGinley et al.
patent: 4960814 (1990-10-01), Wu et al.
patent: 4968350 (1990-11-01), Bindschaedler et al.
patent: 5025004 (1991-06-01), Wu et al.
patent: 5326572 (1994-07-01), Mehra et al.
patent: 5356634 (1994-10-01), Wu et al.
patent: 5380790 (1995-01-01), Chen et al.
patent: 5512092 (1996-04-01), Maruyama et al.
patent: 5646151 (1997-07-01), Kruse et al.
patent: 5723151 (1998-03-01), Cook et al.
Neurath, et al., "3-Hydroxyphtaloyl-.beta.-lactoglobulin. I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted human immunodeficiency virus type 1", Antiviral Chemistry & Chemotherapy, 1196, vol. 8(2), pp. 131-139.
Neurath, et al., "3-Hydroxyphthaloyl-.beta.-lactoglobulin. II. Anti-human immunodeficiency virus type 1 activity in in vitro environments relevant to prevention of sexual transmission of the virus", Antiviral Chemistry & Chemotherapy, 1997, vol. 8(2); pp. 141-148.
Neurath, et al., "A herpesvirus inhibitor from bovine whey", The Lancet, vol. 347, Jun. 15, 1996, p. 1703.
Jiang, et al., "Virucidal and Antibacterial Activities of 3-HP-.beta.-LG", 1997, Vaccines 97, pp. 327-330.
Jiang, et al, Chemically Modified Bovine .beta.-Lactoglobulin Blocks Uptake of HIV-1 by Colon-and Cervix-Derived Epithelial Cell Lines, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1996, vol. 13, pp. 461-462.
Neurath, et al., "Bovine .beta.-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD 4 cell receptor for HIV", Nature Medicine, vol. 2, No. 2, 2-1996, pp. 230-234.
Debnath Asim Kumar
Dow Gordon Jay
Jiang Shibo
Neurath Alexander Robert
Strick Nathan
Azpuru Carlos
New York Blood Center Inc.
LandOfFree
Method for decreasing the frequency of transmission of viral inf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for decreasing the frequency of transmission of viral inf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for decreasing the frequency of transmission of viral inf will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1320926